Since its inception, Nektar has led with scientific ingenuity, unwavering resilience and a bold commitment to improving patients’ lives. We have built expertise spanning foundational scientific research, cutting-edge therapeutic discovery, clinical development, strategic partnerships and commercialization – all in pursuit of opportunities to improve outcomes for people with immune-mediated disease. Through the years, we have developed a proven track record of translating groundbreaking research into innovative therapies in partnership with leading pharmaceutical companies. We remain focused on advancing scientific discoveries into safer, more effective treatments for people living with autoimmune diseases and inflammatory conditions.
Looking for a particular Nektar Therapeutics employee's phone or email?
The Nektar Therapeutics annual revenue was $93.2 million in 2026.
Rob Chess is the Chairman (1999-present), CEO (1992-99, 2006-7), President (1991-92) of Nektar Therapeutics.
357 people are employed at Nektar Therapeutics.
Nektar Therapeutics is based in San Francisco, California.
The NAICS codes for Nektar Therapeutics are [541711, 54171, 541712, 54, 325, 5417, 32, 541].
The SIC codes for Nektar Therapeutics are [372, 37, 28, 283].